Holocene Advisors LP Acquires 62,953 Shares of Amedisys, Inc. (NASDAQ:AMED)

Holocene Advisors LP boosted its stake in Amedisys, Inc. (NASDAQ:AMED - Free Report) by 391.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 79,036 shares of the health services provider's stock after purchasing an additional 62,953 shares during the period. Holocene Advisors LP owned about 0.24% of Amedisys worth $7,628,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of the company. SG Americas Securities LLC raised its holdings in shares of Amedisys by 41.6% in the 2nd quarter. SG Americas Securities LLC now owns 38,315 shares of the health services provider's stock worth $3,517,000 after acquiring an additional 11,264 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Amedisys by 4.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 514,166 shares of the health services provider's stock valued at $47,202,000 after buying an additional 19,660 shares during the last quarter. Cetera Advisors LLC purchased a new stake in Amedisys in the 1st quarter valued at about $1,556,000. Murchinson Ltd. increased its stake in Amedisys by 69.2% in the 2nd quarter. Murchinson Ltd. now owns 123,979 shares of the health services provider's stock valued at $11,381,000 after buying an additional 50,716 shares during the last quarter. Finally, Bardin Hill Management Partners LP increased its stake in Amedisys by 21.5% in the 2nd quarter. Bardin Hill Management Partners LP now owns 120,471 shares of the health services provider's stock valued at $11,059,000 after buying an additional 21,330 shares during the last quarter. Institutional investors own 94.36% of the company's stock.

Amedisys Stock Performance

Shares of AMED stock traded down $1.29 during trading hours on Wednesday, hitting $84.98. 1,379,803 shares of the company were exchanged, compared to its average volume of 369,159. The firm has a fifty day simple moving average of $94.41 and a 200 day simple moving average of $95.53. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05. Amedisys, Inc. has a 52-week low of $84.06 and a 52-week high of $98.95. The stock has a market capitalization of $2.78 billion, a price-to-earnings ratio of 34.23, a P/E/G ratio of 1.92 and a beta of 0.73.

Amedisys (NASDAQ:AMED - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The health services provider reported $1.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.19 by ($0.19). Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The company had revenue of $587.67 million for the quarter, compared to analysts' expectations of $586.75 million. During the same quarter in the previous year, the business earned $0.98 EPS. The company's revenue for the quarter was up 5.7% on a year-over-year basis. Research analysts predict that Amedisys, Inc. will post 4.53 earnings per share for the current fiscal year.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.